2026-03-24 Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates
2026-03-18 Spatial heterogeneity of MDSCs mediated by ANXA1-FPRs signaling drives immune suppression in OSCC progression
2026-03-17 DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling
2026-03-16 Conductive coordination nanozyme prodrugs precisely trigger pyroptosis, cuproptosis and ferroptosis for in situ cancer vaccination
2026-02-26 PD-1 protects expanding human T cells from premature restimulation-induced cell death by modulating TCR and CD28 signaling
2026-02-18 Low-affinity binding of anti-B7-H3 clone MJ18 to murine B7-H3 fails to induce tumor regression
2026-02-12 Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy
2026-02-12 Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy
2026-02-10 A synthetic system for RNA-responsive pyroptosis based on type III-E CRISPR nuclease-protease
2026-02-10 Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8+ T cells in lymph nodes
2026-02-09 Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer
2026-02-09 STING synergizes with TOX suppressing HO-1 expression to trigger ferroptosis in tumor-infiltrating CD8+ T cell and immunotherapy resistance
2026-02-09 Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16–CXCR6 signaling for potent antitumor response
2026-02-05 Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development
2026-02-03 Dynamic magneto-mechanical force in lysosomes induces durable macrophage repolarization for antitumor immunity
2026-02-02 Automated quantification of tumor-infiltrating lymphocytes by machine learning reveals prognostic and immunogenomic features in lung cancer
2026-02-02 Structural mechanism of anti-MHC-I antibody blocking of inhibitory NK cell receptors in tumor immunity
2026-01-28 Endothelial PDLIM5 promotes tip cell filopodia formation and tumor angiogenesis by regulating ACTN1/ACTN4-dependent actin bundling
2026-01-28 Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety
2026-01-27 Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade
2026-01-26 Stenotrophomonas promotes gastrointestinal tumor progression via STING degradation in tumour cells and mitigated immune response
2026-01-26 A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities
2026-01-26 Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice
2026-01-24 CISH, a key intracellular checkpoint, in comparison and combination to existing and emerging cancer immune checkpoints
2026-01-23 NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes
2026-01-22 MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation
2026-01-21 In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy
2026-01-19 Cell cycle arrest enhances CD8+ T cell effector function by potentiating glucose metabolism and IL-2 signaling
2026-01-16 BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells
2026-01-16 Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy
2026-01-16 Oral Lentinula edodes mycelia extract enhances the antitumor effect of radiotherapy via gut-associated activation of dendritic and cytotoxic T cells
2026-01-14 Tumour immune contexture and immune evasion in sporadic and Lynch syndrome-associated microsatellite unstable colorectal cancers
2026-01-13 Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
2026-01-07 Monovalent pseudo-natural products supercharge degradation of IDO1 by its native E3 KLHDC3